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Abstract
Background: Breast cancer is the most common type of cancer in women in the developed world. As a result of breast
cancer treatment, many patients suffer from serious complaints in their arm and shoulder, leading to limitations in activities
of daily living and participation. In this systematic literature review we present an overview of the adverse effects of the
integrated breast cancer treatment related to impairment in functions and structures in the upper extremity and upper
body and limitations in daily activities. Patients at highest risk were defined.
Methods and Findings: We conducted a systematic literature search using the databases of PubMed, Embase, CINAHL and
Cochrane from 2000 to October 2012, according to the PRISMA guidelines. Included were studies with patients with stage I–
III breast cancer, treated with surgery and additional treatments (radiotherapy, chemotherapy and hormonal therapy). The
following health outcomes were extracted: reduced joint mobility, reduced muscle strength, pain, lymphedema and
limitations in daily activities. Outcomes were divided in within the first 12 months and .12 months post-operatively.
Patients treated with ALND are at the highest risk of developing impairments of the arm and shoulder. Reduced ROM and
muscle strength, pain, lymphedema and decreased degree of activities in daily living were reported most frequently in
relation to ALND. Lumpectomy was related to a decline in the level of activities of daily living. Radiotherapy and hormonal
therapy were the main risk factors for pain.
Conclusions: Patients treated with ALND require special attention to detect and consequently address impairments in the
arm and shoulder. Patients with pain should be monitored carefully, because pain limits the degree of daily activities. Future
research has to describe a complete overview of the medical treatment and analyze outcome in relation to the treatment.
Utilization of uniform validated measurement instruments has to be encouraged.
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Introduction
Breast cancer is the most common type of cancer in women in
the developed world. Due to new treatment modalities, breast
cancer survival has improved over time. However, as a result of
breast cancer treatment, many patients suffer from adverse effects
and have serious complaints in their arm and shoulder e.g.
decreased joint mobility, muscle strength, pain and lymphedema,
leading to limitations in activities of daily living and participation
in work, sports and leisure activities. [1–3] In a prospective
Australian study, 62% of the population still suffered from at least
one impairment as a complication of breast cancer treatment and
27% suffered from two to four impairments after six years. [4]
Reported variability in onset and severity of upper limb symptoms
of patients with breast cancer reported in studies is large [5] and a
systematic overview of risk factors related to medical treatment is
lacking. This information is of direct clinical relevance, as early
physical therapy intervention for these complaints as well as
surveillance of patients at risk for developing impairments in daily
activities reduces the need for intensive rehabilitation and the
associated costs. [6] Based on the misconception that disabilities
such as decreased range of motion, pain and lymphedema will
resolve over time without intervention, combined with denial of
the possible benefits of physical therapy interventions, this has led
to the inadequate monitoring of disabilities. [7] To the best of our
knowledge, this is the first systematic review with an evidence
synthesis on the physical adverse effects of all components of breast
cancer treatment, analyzed for each treatment modality, on
impairments in the arm and shoulder, leading to limitations in
activities that potentially warrant treatment. If the clinician is
aware of the risk of adverse effects of the treatment, clinical
reasoning regarding surveillance and the early detection of
impairments in patients at risk can be applied in a systematic way.
In this article, we present a systematic literature review of the
adverse effects of breast cancer treatment in terms of development
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of constraints in the arm and shoulder in patients with stage I–III
breast cancer who underwent curative treatment. We describe the
adverse effects for treatment-induced disorders of the musculo-
skeletal system - classified by International Classification of
Functioning, Disability and Health (ICF) domains [8] - and assess
the influence of pre-existing comorbidity. More specifically, the
following key question is answered in this systematic review: which
adverse effects related to breast cancer treatment predict persistent
impairments in function and structures of the upper extremities/
thorax, e.g. reduced joint mobility, reduced muscle strength, pain,
lymphedema and limitations in daily activities?
Methods
Study selection criteria
Search strategy. We conducted a systematic literature search
using the databases of PubMed, Embase, CINAHL and
Cochrane. Published studies in English, French and German
language were eligible for inclusion. We started with the inclusion
of eligible meta-analyses and systematic reviews, and then
considered the inclusion of prognostic cohort studies, case-control
studies and cross-sectional studies that were not included in
published systematic reviews. To minimize bias, only studies with
at least 100 patients were included. Studies which had already
been included in systematic reviews or meta-analyses were not
analyzed separately. To allow for an adequate follow-up and
description of late adverse effects, only studies with a follow-up
period of at least 3 months were included. When more publica-
tions of the same study were published, data were extracted from
the most recent publication. As we were merely interested in
adverse effects in relation to current medical practice, studies
published from January 2000 to October 2012 were included. The
search strings are listed in table 1.
Patients. Studies on patients with curatively treated breast
cancer (Stage I–III) were included.
Intervention. Included medical interventions were: surgery
(mastectomy, lumpectomy, axillary lymph node dissection
[ALND], sentinel node biopsy [SNB], and breast reconstruction)
and additional treatments (radiotherapy, chemotherapy and
hormonal therapy).
Outcomes. The following health outcomes were extracted:
impairment in functions and structures in the upper extremity and
upper body (reduced joint mobility, reduced muscle strength, pain,
and lymphedema), and limitations in daily activities of the upper
extremity. Outcomes had to be measured with instruments for
which validation studies were published, or for which the authors
described validation before initiation of the study.
Description of adverse effects of the medical treatment was
divided into effects within the first 12 months and late effects (.
12 months). When outcome measures of severe cases were
presented as well, these were presented between brackets in table 2.
Quality assessment
We evaluated the methodological quality of the included studies
to test generalizability and possible bias. Studies were rated using
the Oxford Centre for Evidence-Based Medicine, 2011 appraisal
sheets and levels of evidence (see table 3) [9]. Two authors (JH +
CB) independently scored each item of the appropriate scoring
sheet. Disagreements were discussed together or if appropriate in
the research group. If the item was well described and its quality
was good, a plus (+) was assigned, plus-minus (6) was assigned if
the item was incompletely described, and minus (–) was used if the
item was not clearly described or not described at all. Five items
were used to score systematic reviews leading to a maximum score
of 100% (see table 4 and 5). Only systematic reviews including
meta-analysis could achieve a full score of 100%. For cohort
studies, six items were scored. Since the type of surgical treatment
may influence health outcomes, articles describing radiotherapy
treatment not taking into account the type of surgical treatment
were given no score to the item ‘‘Subgroups with different
prognosis identified’’. A full score was assigned to studies assessing
the outcome ‘‘lymphedema’’ with measurements of the full arm,
using tape measurements to calculate volume, water volumetry,
perometry or bio-impedance spectroscopy (BIS). When other
methods of multiple tape measurement were used, plus-minus was
assigned to ‘‘validated outcome’’ criterion. If the Common
Terminology Criteria for Adverse Events (CTCAE) was used as
a measurement instrument for lymphedema no score was given,
because only one location was measured. Questionnaires on
lymphedema were given plus-minus, as these questionnaires led to
a higher incidence percentage in relation to volumetric measure-
ments. [10] In selecting studies with a quality score of .50% we
aimed at reducing the risk of bias of the included studies resulting
in more robust conclusions of our review.
Synthesis
First, we described detailed characteristics and the main findings
of the included systematic reviews, RCTs, and cohort studies, as
reported by the authors of the included studies. Second, we
assessed adverse effects per impairment and activity limitations for
each medical intervention and combination of medical interven-
tions. Adverse effects were assessed for short-term impact (#
12 months follow-up) and long-term impact (.12 months follow-
up). If a study did not identify which part of the treatment caused
Table 1. Search string adverse effects.
Pubmed
(((((("Breast Neoplasms" [Mesh] OR "Breast Neoplasms" OR "breast cancer")) AND (surgery))) AND (((((radiotherapy)) OR (((("Breast
Neoplasms/drug therapy" [mesh])) OR ("Antineoplastic Agents" [Mesh])) OR ("chemotherapy" [All Fields]))) OR ("Antineoplastic
Agents" [Pharmacological Action])) OR (hormonal therapy)))) AND (((((((((activities)) OR ("Activities of Daily Living" [Mesh]))) OR
(range of motion)) OR (("Muscle Strength" [Mesh]) OR "Range of Motion, Articular" [Mesh])) OR (muscle strength)) OR
(Lymphedema)) OR (pain)) AND (dutch [la] OR english [la] OR german [la] OR french [la]) AND ("2000/01/01" [PDAT] : "3000/12/31"
[PDAT])
Cinahl TI breast cancer AND ((AB "Range of Motion" ) OR (AB "Muscle Strength’’) OR (AB Lymph*) OR (AB ‘‘Activities of Daily Living’’ ) OR (AB pain)) Limiters:
Published Date from: 20000101–20121231 Language English
Embase breast cancer.ti. AND ((activities of daily living.ab.) OR (range of motion.ab.) OR (muscle strength.ab.) OR (muscle strength.ab.) OR (Lymphedema.ab.)
OR (pain.ab.)) Limit to (english language and yr = ‘‘2000– 2012’’)
Cochrane Topic ‘breast cancer’ AND ‘adverse effects’
doi:10.1371/journal.pone.0096748.t001
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Table 2. Outcome of the studies regarding breast cancer treatment and adverse effects.
Author/year of
publication Design
Disease stage/treatment/
number of pts included
Number of studies/Dates
of inclusion/FU in months
(% FU if mentioned)
Measurement
instruments in
outcome Main findings
Hickey et al.
2013
SR Concurrent RT + CT vs.
sequential n = 107/107/RT
then CT vs. CT then RT,
n = 117/119 for LE; n = 42/43
for brachial neuropathy
3 studies: RCT; 3 survival, 2
toxicity/Up till Dec. 2011;
60/135months (FU 74%)
CTCAE/LENT-SOMA Late toxicity 29% ; Concurrent vs.
sequential RT after CT: Grade III/IV, in
favour of sequencing: atrophy OR= 2.09
(CI = 0.92–4.75); fibrosis OR = 13.77
(CI = 0.77–247.54);LE OR= 2.02 (CI = 0.18
to 22.61). RT before CT vs. CT before
RT: In favour of RT first: LE OR= 2.11
(CI = 0.67–7.21) ; Brachial neuropathy
OR= 3.14 (CI = 0.12–79.39)
Moja et al.
2012
SR Stage I-III/HER2 pos. BC/
Trastuzumab + CT vs. CT
alone(Anthracyclines,
Taxanes,Vinorelbine, other
CT); CHF n = 5471/4810;
LVEF n = 4147/3792
8 studies: RCT 8/1996-Feb.
2010/% FU missing/
$ 24 months
Cardiac toxicity (CHF,
LVEF), other toxicities
Trastuzumab vs. no trastuzumab:
CHFq, cardiac toxicityq, LVEFQ; CHF:
trastuzumab administration .6 months
OR= 5.11; Cardiac toxicity: trastuzumab
before CT OR= 8.42; CT before
trastuzumab OR=11.05; Concurrent CT/
trastuzumab OR=3.90 (overall .6
months OR= 5.12); LVEFQ OR=1.83;, 6
months OR = 0.89; .6 months OR=
2.14. Trastuzumab before CT:
OR= 1.16. CT before trastuzumab:
OR= 2.90, Concurrent CT/trastuzumab:
OR= 1.48
Zhou et al.
2011
SR Stage I–IV/Zoledronic acid/
ZOL vs. no ZOL n= 2684/
2712/Delayed ZOL vs.
upfront ZOL n = 119/284
4 studies: RCT 4/Up till May
2011 (Art 1. CT [mostly
anthracycline] +/2 HT;
Art 2. Gosselerin + tamoxifen
or anastrozole; Art 3/4
adjuvant treatment not
specified/% FU missing/
12–60 months
Not described ZOL vs. no ZOL: q arthralgia (4
studies); q bone pain (2 studies);
arthralgia RR = 1.16; bone pain RR = 1.26;
muscle pain no differences between
groups; complications 0.2–0.8% per item.
Delayed vs. upfront ZOL: No
differences between groups for bone
pain/arthralgia; arthralgia RR = 1.28.
Anastrozole alone vs.. tamoxifen
alone: arthralgia 25% vs. 12% ; bone pain
(28% vs. 21%) (art 2). Anastrozole +
ZOL vs. tamoxifen + ZOL: bone pain
35% vs. 25%; arthralgia 24% vs. 18% (art
2)
Levangie et al.
2009
SR ALND/SNB/RT/Breast
cancer vs. non breast cancer
n = 1501/ALND vs. SNB vs.
none/n = 2353/996/59
36 studies: CS 7; CCT 11;
prospective 10; retrospective
1; CSS 2; RCT 5/1980–2008/%
FU missing/12–126 months
ROM, muscle strength/
grip strength/upper
body functions
ALND vs. SNB or non-affected side:
ROMQ flexion, abduction and abduction/
external rotation; OR = 1.02/2.65/9.0*.
Muscle strength Q grip strength,
resistance abduction; OR = 8.82. Pain
OR= 3.54 (1.88–6.66). Upper arm activities
q limitations compared to non-breast
cancer; Q: ALND OR= 3.18/9.23*. RT vs.
no RT: OR= 1.32/2.64/4.67*
Liu et al. 2009 SR SNB vs. SNB + ALND vs.
ALND/RT/n = 7135 vs. 1225
vs. 1445.
17 studies: RCT 5, CCT 12:
prospective 9, retrospective
3/SNB vs. SNB + ALND vs.
ALND/1993–2008/% FU
missing/6–72 months
ROM, Hand-held
dynamometer, MPQ,
VAS, tape
measurement, MASS
SNB: 6 months: LE 3–10%. 12 months:
ROMQ 6–31%; RT OR= 2.6; muscle
strength Q 17–19%; pain 8–36%; LE 6–
14%. 24 months: Pain 8–21%; upper arm
activitiesQ: RT axilla OR = 2.6. 36
months:ROMQ0–9%. 60 months (1 study,
SNB): Muscle strengthQ11%; pain 9%; LE
7%; axillary RT OR=2.4; sleep disturbance
9%
Tsai et al.
2009
SR ALND/SNB/RT/ALND vs.
SNB n = 8262/Objective
measurements n = 23964
98 studies: 10 RCT’s, 83
CCT: 40 prospective, 43
retrospective, 5 CSS/ALND
vs. no ALND/13 studies/
Radical mastectomy vs.
other mastectomy 8 studies/
1950–2008/% FU missing/
1–360 months
Tape measurement,
BIS, water
displacement,
self-report
ALND vs. SNB: LE RR = 3.07; ALND vs.
no ALND: LE RR = 3.47; Radical
mastectomy vs. other mastectomy:
LE RR = 3.28; RT axilla vs. RT no axilla:
LE RR = 2.97
Lee et al.
2008
SR Surgery/RT not axilla/
n = 5154/LE risk n = 2416/
ROMQ risk n = 476
25 studies: RCT 8; CCT24:
prospective 17, retrospective
7/1966–2007/% FU missing/7
wks-203 months
ROM, VAS, tape
measurement, water
displacement, LENT-
SOMA, EORTC-QLQ
ALND vs. SNB: ROMQ 1%–67%; most
problems 7–12 months post-surgery;
muscle strengthQ 9%–28%; OR= 4.61;
pain 9%–68%; OR= 3.03; LE 0%–34%;
OR= 11.67; RT not axilla OR = 1.46;
Shoulder complaints: OR = 9.8
Impairments in Arm and Shoulder in Breast Cancer
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Table 2. Cont.
Author/year of
publication Design
Disease stage/treatment/
number of pts included
Number of studies/Dates
of inclusion/FU in months
(% FU if mentioned)
Measurement
instruments in
outcome Main findings
Ashikaga
et al. 2010
RCT Stage not described/SNB
+ ALND vs. SNB (+ ALND
in case of positive nodes)/
RT/CT/n = 5611
36 months Abduction ROM,
water displacement
ALND vs. SNB: 2–3 weeks: ROM:
abductionQ: 56% vs. 21%. 6 months:ROM
abductionQ: 9% vs. 6%; ALND OR= 1.56;
RT axilla OR = 2.48, CT OR= 0.73; LE: 13%
vs. 9%. 12 months:LE: 13% vs. 9%. 36
months:LE: 14% vs. 8%; Q age (+/250
years) OR = 1.41, dominant affected arm
OR= 1.77, RT axilla OR = 3.47
Andersen
et al. 2012
CCT Stage not described/Surgery/
RT/CT: CEF vs. CE+T/HT/
n = 2893
35/24 months NPRS, Sensory
disturbances in
hands and feet
Pain overall 53%; activities: 34% gave up.
CEF vs. CE+T: Sensory disturbances in
both hands: 15% vs. 23%; OR= 1.56.
Sensory disturbances in both feet: 18% vs.
32%; OR= 2.00; in younger patients
OR= 0.45; q risk of giving up activities
OR = 1.59
Miller
et al.
2012
CCT Stage not described/ALND
vs. SNB/Mastectomy/n = 117
29 (3–64) months Water displacement;
perometer; LEFT-BC
Questionnaire
ALND vs. SNB: LE: 3 vs. 0%; ALND: q
subjective symptoms; qMean weight-
adjusted water displacement change
Ozcinar
et al. 2012
CCT Stage I–II, cT1,2 N0/SNB vs.
ALND/RT vs.. RT axilla vs.
RT regional LN/n = 221
(99%); 64 (24–82) months Tape measurement
10 cm above and
below elbow
Lymphedema: 9–12 months: 25%. 64
months: 7% (Qby treatment LE)
Taira et al.
2011
CCT ALND level I–III/Mastectomy
vs. lumpectomy + RT/n = 196
FU 97% at 1 months; 96%
at 6 months; 95% at 12
months; 80% at 24 months
FACT-G/FACT-B Mastectomy vs. lumpectomy + RT: 1
month (severe): ROMQ 68 (15)% vs. 73
(14)%; muscle strengthQ 67 (10)% vs. 72
(18)%; pain 75 (18)% vs. 82 (20)%;
lymphedema 27 (1)% vs. 41 (7)%; upper
arm activities: LiftingQ 83 (25)% vs. 88
(20)%; household choresQ 61 (4)% vs. 64
(13)%; self-careQ 56 (4)% vs. 63 (9)%;
physical activitiesQ 73 (19)% vs. 76 (19)%.
1 year (severe):ROMQ 32 (4)% vs. 40 (7)%;
muscle strengthQ 48 (7)% vs. 51 (5)%;
pain 60 (12)% vs. 63 (7)%; lymphedema
26 (3)% vs. 48 (11)%; upper arm activities:
LiftingQ 34 (2)% vs. 39 (3)%; household
choresQ 28 (4) vs. 33 (1)%; self-careQ 16
(0)% vs. 12 (1)%; physical activitiesQ 41
(4)% vs. 39 (4)%. 2 years (severe):ROM 23
(0)% vs. 30 (4)%; muscle strengthQ 39
(5)% vs. 56 (7)%; pain 42 (8)% vs. 56 (5)%;
lymphedema 33 (10)% vs. 52 (15)%; upper
arm activities: LiftingQ 20 (1)% vs. 39 (4);
household choresQ 18 (1)% vs. 21 (3)%;
self-careQ 10 (0)% vs. 14 (4)%; physical
activities: 34 (7)% vs. 31 (5)%
Wernicke
et al. 2011
CCT stage I–II/ALND vs. SNB/
n = 265
119 months ROM, tape
measurement
ALND vs. SNB: ROMQ ; Lymphedema
35% vs. 5%
Land et al.
2010
CCT Node negative invasive BC/
ALND vs. SNB/Mastectomy
vs. lumpectomy/n = 747
36 months Questionnaire
adapted from DASH
ALND vs. SNB: Upper arm activitiesQ. 6
and 12 months: ALND group: q arm use
avoidance. Mastectomy vs.
lumpectomy (+ ALND): Lumpectomy:
q problems with shoulder/arm function,
conducting social and work activities
Yen et al.
2009
CCT Stage I–IV/ALND vs. SNB/
Mastectomy vs. lumpectomy/
RT/CT/HT/n = 1338
48 months Telephone interviews:
arm functioning
related to LE, pain,
or tenderness in the
arm or hand on the
side of surgery
Lymphedema 14% (self-report). q LN
removed: 6–10 nodes OR= 4.68; 11–15
nodes OR= 5.61; .16 nodes OR= 10.50
Bevilacqua
et al. 2012
CoS Stage II–IIIa/ALND level I–III/
n = 1243
(84%); 60 months Tape measurement Lymphedema 30% at 60 months; curveQ
increasing after 36 months. Nomogram ,
6 months: age, BMI, level of ALND;
nomogram .6 months: age, BMI, level of
ALND, seroma, early LE
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Table 2. Cont.
Author/year of
publication Design
Disease stage/treatment/
number of pts included
Number of studies/Dates
of inclusion/FU in months
(% FU if mentioned)
Measurement
instruments in
outcome Main findings
Levy et al.
2012
CoS Stages 0-III/ALND/SNB/-/
Mastectomy/lumpectomy/
Breast reconstruction/
n = 115
.12 months ROM, MRC-scale, NPRS,
perometer, ULDQ, PAQ,
BMI
1 month: ROM flexion/abductionQ 60%;
external rotation Q 25%. ROMQ: ALND,
q LN removed, mastectomy, stage II,
hand dominant side, cording, seroma,
BMI $25. ROMq: q level of PA. 12+
months:Flexion/abduction 11/10%;
external rotation Q 5%; muscle
strengthQ: 47%; pain 49% (11%
moderate); fatigue 43%. ROMQ: positive
LN, mastectomy (flexion), older age (.65
yrs), BMI $25. Heavy household chores
Q: feeling stiff OR = 4.60; feeling week
OR= 9.67; pain OR= 6.16; LE OR= 4.16;
fatigue OR= 9.33; lifting a gallonQ:
feeling week: OR = 6.34; pain: OR = 4.58
Mieog et al.
2012
CoS Stage I–III/Tamoxifen vs.
exemestane/n = 4724
91 months CTCAEv1 for CTS and
MSD
CTS 2%; MSD 43%. Exemestane vs.
Tam: OR = 9.90 for CTS. Independent
risk factors: HT, history of musculoskeletal
symptoms, arthralgia, myalgia,
osteoarthritis
Schmitz et al.
2012
CoS Stages I–III+/ALND vs. SNB
vs. –/Mastectomy vs.
lumpectomy/RT/CT/HT/
n = 287
(70.7%); 72 months tape measurement,
BIS, DASH, FACT-B+4
Adverse effects: 6 months:$1: 90%; 2–4:
72%; .4: 16%; 12 months: $1: 69%; 2–4:
46%; 18 months: $1: 66%; 2–4: 34%; 72
months:$1: 62%; 2–4: 27%
Kanematsu
et al. 2011
CoS Stage 0-IV (1 x IV)/
Aromatase inhibitors/
CT/n = 391
40 (9–120) months CTCAEv4 Age ,55 vs. 55–65 vs. .65 years:
Arthralgia 46% vs. 37% vs. 28%; pain
frequencyq: Q age at menarche; pain
frequencyQ: time since last menstrual
period .10 years; HT/CT/disease stage ns
Ridner et al.
2011
CoS Stages I–IV/ALND/SNB/
RT/n = 138
30 months Perometer, Weight,
LBCQ
Lymphedema 20% ; BMI $30 OR=3.59;
adjusted for ALND as risk factor OR = 4.12;
80% of LE patients heaviness
Rief et al.
2011
CoS Early stage BC/Mastectomy/
lumpectomy/HT/n = 2160
48 months Symptom Inventory,
METs, RAND36, Life
Orientation Scale—
Revised, MOS,
Pain q: pain or depression at baseline,
life events first 12 months post-operative,
TAM at baseline. Pain Q : qexercise, q
years since diagnosis, q education. Pain
scoresq: stage II lumpectomy, and stage
I mastectomy
Devoogdt et al.
2010
CoS Stage 0-IV/ALND/SNB/
n = 267
(88%); 24 months FPACQ, MET-hours/
week
Activities: MET’s per week: Preoperative:
269; 3 months: 244; 6 months: 246; 12
months: 258. MET’sQ: q in younger age,
being employed, ductal carcinoma
Chang & Kim
2010
CoS Stage not described/Free
flap, Latissimus dorsi flap/
n = 482
17 months missing Lymphedema 8% pre-existing; 4%q after
reconstruction; LEQ: delayed autologous
reconstruction
Johnsson
et al. 2010
CoS Early stage BC/ALND/SNB/
RT breast/chest wall/
regional LN/CT/n = 100
10 months Return to work 25%/5
hours; Li-Sat11; GCQ
Return to work: 6 months: 66%; 10
months: 83%. Return to workQ:At 6
months: CT,.30 days of sick leave during
the previous 12 months, Q satisfaction
with current capacity in ADL; at 10
months: RT breast/chest wall/regional LN,
Q satisfaction with work
Kwan et al.
2010
CoS Stages I–IV/ALND/SNB/RT/
CT/n = 997
21 (1–32) months CTCAE v.3.0; ICD;
lymphedema
treatment;
compression device
Lymphedema: 12 months: 10%; 24
months: 14%. Model 1: ICIDH: African
American,qeducation, each LN removed
4.1%q; Model 2: LE treatment: CT; Model
3: Durable medical equipment associated
with BC related LE: being obese
Norman et al.
2010
CoS Stage I–IV/ALND/SNB/RT/
CT/n = 4551
(86%); 12–60 months Face to face interview
followed by telephone
interview
Lymphedema 14%. CT HR=3.16; Multi-
agent CT with anthracycline HR= 3.76
Impairments in Arm and Shoulder in Breast Cancer
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Table 2. Cont.
Author/year of
publication Design
Disease stage/treatment/
number of pts included
Number of studies/Dates
of inclusion/FU in months
(% FU if mentioned)
Measurement
instruments in
outcome Main findings
Yang et al.
2010
CoS ALND/SNB/Mastectomy/
Lumpectomy/Adjuvant
treatment/n = 183
12 months MPS, Hawkins’ test,
supraspinatus test,
and Neer’s test,
PMPS, AWS, tape
measurement
ALND vs. SNB vs. lumpectomy:
Lymphedema 18%; upper arm activities
Q. At 3 months:39% vs. 18% vs. 12%; at 6
months:40% vs. 12% vs. not described %;
at 12 months: 44% vs. 19% vs. 18%.
Rotator cuff disease 12 months associated
with pectoralis tightness and LE at 3
months
Sagen et al.
2009
CoS Stage I–III/ALND level
I–II/n = 204
60 months VAS, water
displacement,
EORTC-QLQ-C30, self-
generated
questionnaire
At 6 months:Pain during activities vs. at
rest 56% vs. 60% ; lymphedema 7%;
upper arm activities: function scores Q
(from 30 points to 29 points). At 60
months:Pain during activities vs. at rest
36% vs. 30% ; lymphedema 13%; physical
activity at leisure time at baseline and 6
months predictive for physical
functioning at 5 years
Paskett et al.
2007
CoS Stage I–III Surgery/
reconstruction/RT/CT/
HT/n = 622
(93%); 36 months BMI, self-generated
questionnaire, SF12,
FACT-B
LE 54%; predictive: tamoxifen
Lundstedt
et al. 2012
CSS Stage not described/ALND
vs. SNB/RT vs. RT SC/n = 814
36–96 months CTCAE ALND + RT vs. ALND vs. SNB/no RT:
LE 22% vs. 15 vs. 5%. LEq: RT SC
Sheridan
et al. 2012
CSS Stage not described/
Surgery/RT/CT/HT/n = 111
64 months S-LANSS, CPAQ,
HADS
Pain VAS 32626. Pre-operative: 18%; Risk
of chronic painq OR=5. Post-operative:
36%; 23% intermittent pain; 32%
exacerbation by exercise; q chronic pain
related to anxiousness, CT
Dahl et al.
2011
CSS Stage II–III/Surgery/RT/
n = 337
30 months Self-generated
questionnaire, EORTC-
QLQ-C30-BR23, FQ,
HADS, SF-36
Pain arm/shoulder 37%; sleep disturbance
30%; qdisability pension, depression,
anxiety. Sleep disturbance q: arm/
shoulder pain OR= 2.46; LE OR= 2.34; Q
ROM OR= 2.63
Nesvold
et al. 2011
CSS Stage II–III/Surgery/RT/
n = 349
(56%); 83–113 months ROM flexion/abduction,
tape measurement,
KAPS, EORTC-QLQ-BR23,
IOC, SF36
ROM Q 33%; pain sign. related to arm-
shoulder problems; lymphedema 17%;
upper arm activities Q 31%
Shamley
et al. 2009
CSS Stage not described/ALND
vs. SNB/Mastectomy vs.
lumpectomy/RT/CT/n = 152
6–72 months Polhemus FastrakTM,
SPADI
Pain: 0–24 months 26%; 24–48 months
43%; 48–72 months 32%. Upper arm
activities: 0–24 months 26%; 24–48
months 43%; 48–72 months 32%.
Affected side vs. unaffected side: All
scapulothoracic movements sign. altered:
Right scapulothoracic lateral rotation
differences associated with downward
movement; left scapulothoracic
dysfunction (q protraction, q posterior
tilt, Q lateral rotation): CT. Pain and
disability associated with scapulothoracic
dysfunction; scapulothoracic movements:
q difference when left side affected
Park et al.
2008
CSS Stage I–III/Mastectomy/RT/CT/
n = 450
12–24 months Tape measurement Lymphedema 25%; disease stage
(OR = 2.58 for stage II; OR = 2.84 for stage
III); modified radical mastectomy
OR= 7.48; ALND OR= 6.61; axillary RT
OR= 6.73; CT; overweight OR= 2.01; non
exercise vs. exercise OR= 1.24; not
receiving pre-treatment education
OR= 2.26; Q preventive self-care
activities
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the adverse effects, the study was excluded from the analysis of
outcome measures. Third, we assigned a level of evidence for each
of the adverse effects related to the common harms of the medical
intervention. [9] We anticipated on using a quantitative assess-
ment in a meta-analysis, but due to the heterogeneity of outcome
measures, adverse effects, and (combinations of) medical treatment
we were unable to pool data from separate studies.
Results
We identified 804 unique articles, of which 116 were eligible for
full-text assessment (see figure 1 for a flow diagram). Of these, 54
studies were excluded because they did not meet the inclusion
criteria. Another 23 studies were excluded because they had
already been included in one or more systematic reviews(15) or
had a quality rating #50% (8). Finally, 39 articles were included.
In the syntheses 13 articles could not be included because adverse
effects were not analyzed separately for each treatment modality.
Table 2. Cont.
Author/year of
publication Design
Disease stage/treatment/
number of pts included
Number of studies/Dates
of inclusion/FU in months
(% FU if mentioned)
Measurement
instruments in
outcome Main findings
Ververs et al.
2001
CSS Stage not described/ALND/
n = 400
3–60 months Tape measurement,
self-generated
questionnaire
Muscle strength Q in 28%. Pain:
comorbidity OR= 3.38. Lymphedema:
Objective .2 cm 71%; severe LE 9%; RT
SC/axilla OR = 3.57; comorbidity OR= 3.08.
Shoulder, neck or back complaints:
comorbidity OR= 2.72. Activities: 25–35%
daily activitiesQ, lifting objectsQ; 14%
problems with transportation; 37% gave
up hobbies or sports
Avraham et al.
2010
CCS SNB +/2 ALND/Mastectomy/
Tissue expander/n = 316
60 months LBCQ, tape
measurement, BMI
Reconstruction vs.. no
reconstruction: LE: 5% vs. 18% (severe
,1% vs.. 4%); (overall 11% objective; 16%
subjective). LEq: Chest wall RT
Mak et al.
2008
CCS ALND/n = 202/230 42612/43614 months Tape measurement,
validated questionnaire
LEq: infection: OR = 3.80; q age at
surgery OR= 1.06 for each year.
Moderate-severe LE: ALND dominant
side, medical procedures on hand/arm,Q
air travel, institution of surgery
Study design: CCT, clinical controlled trial; Cos, cohort study; CSS, cross sectional study; pts, patients; RCT, randomized controlled trial; SR, systematic review.
Intervention: ALND, axillary lymph node dissection; art, article; CE, cyclophosphamide, epirubicin; CEF, cyclophosphamide, epirubicin and fluorouracil; CT,
chemotherapy; FU, follow up; Gy, Grey; HT, hormonal therapy; IMB, internal mammarial boost; IM-MS, internal mammary and medial supraclavicular lymph node chain;
IORT, intra operative radiotherapy; LRRT, locoregional radiotherapy corresponding to periclavicular, axillary level 3, and for right-side breast cancers, the internal
mammary nodes; LN, lymph node; M, metastasis; N, nodal status; PAB, posterior axillary boost; RT, radiotherapy; SC, supra scapular; SNB, sentinel node biopsy; T,
docetaxel; T, tumor; TAM, tamoxifen; vs., versus; wks, weeks; ZOL, Zoledronic Acid.
Measurement instruments: BIS, bio impedance spectroscopy; BMI, body mass index; BSI, Brief Symptom Inventory; CPAQ, Chronic Pain Acceptance Questionnaire; CES-
D, center for epidemiologic studies – depression scale; CTCAE, Common Terminology Criteria for Adverse Events ; DASH, disabilities of arm, shoulder and hand; EORTC-
QLQ-C30-BR23, European organization for research and treatment of cancer – quality of life questionnaire- breast; FACT-G-B, functional assessment of cancer therapy –
general – breast; FLIC, Functional living index – cancer; FQ, fatigue questionnaire; FPACQ, Flemish Physical Activity Computerized Questionnaire; GCQ, general coping
questionnaire; HADS, hospital anxiety and depression scale; ICD, international classification of diseases; IOC, impact of cancer scale; KAPS, Kwan’s arm problem scale;
LANSS, Leeds Assessment of Neuropathic Symptoms and Signs; LBCQ, lymphedema breast cancer questionnaire; LEFT-BC, Lymphedema Evaluation Following
Treatment for Breast Cancer; LENT-SOMA, late effects normal tissue – subjective objective management analytic; Li-Sat, life satisfaction; MASS, measure of arm
symptoms survey; MET, metabolic equivalent ; MOS, medical outcomes study; MPQ, McGill pain questionnaire; MRC-scale, medical research council scale; MSPQ,
Modified Somatic Perception Questionnaire; NPRS, numeric pain rating scale; PAISSR, Psychological Adjustment to Illness Scale-Self-Report; PAQ, physical activity
questionnaire; PSI-B, Problem solving inventory-brief; ROM, range of motion; SF-36, short form-36; SPADI, shoulder pain and disability index; ULDQ, upper limb disability
questionnaire; v, version; VAS, visual analogue scale; WHR, Waist-Hip ratio.
Outcomes: ADL, activities in daily living; AWS, axillary web syndrome; CHF, cardiac heart failure; CTS, carpal tunnel syndrome; HR, Hazard Ratio; LE, lymphedema; LVEF,
left ventricular ejection fraction; ns, non-significant; OR, odds ratio; MPS, myofascial pain syndrome; MSD, musculoskeletal disorders; PA, physical activity; PMPS, Post
Mastectomy Pain Syndrome; RR, relative risk; sign, significant; *, data extracted from included studies.
doi:10.1371/journal.pone.0096748.t002
Table 3. Oxford Centre for Evidence-Based Medicine, 2011 Levels of Evidence for common harms (Treatment harms).
Level 1
Systematic review of randomized trials, systematic review of nested case-control studies, n-of-1 trial with the patient you are raising the
question about, or observational study with dramatic effect
Level 2 Individual randomized trial or (exceptionally) observational study with dramatic effect
Level 3 Non randomized controlled cohort/follow-up study provided there are sufficient numbers to rule out a common harm
Level 4 Case-series, case-control studies or historically controlled studies
Level 5 Mechanism-based reasoning
doi:10.1371/journal.pone.0096748.t003
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Methodological quality of the included studies
The methodological quality of the included studies ranged from
60% to 90% for the systematic reviews (see table 4), and from 58%
to 100% for prognostic studies and RCTs (see table 5). In four
systematic reviews, the search strategy was limited to one database
only. [1,11–13] Results in four systematic reviews were not pooled
due to the heterogeneity of the data. [11,12,14,15] The majority of
the cohort studies presented validated outcome measures, while
seven of the 32 studies described outcome by a self-generated and
self-validated questionnaire [3,16,17] or performed incomplete
measurements. [18–21] In six studies, a description of the outcome
was incomplete. [22–27].
Adverse effects
Table 2 presents a detailed overview of the results of the
included studies. Six systematic reviews and 29 cohort studies
presented analyses regarding the origin of the adverse effects.
Some studies analyzed the relationship of the adverse effects in
relation to comorbidity, age or BMI.
In most studies, different subgroups were identified based on
surgical treatment. Four studies [17,28–30] focused only on
patients that underwent ALND. One systematic review [1] and
one cross-sectional study [27] focused on the adverse effects of
radiotherapy. The adverse effects of aromatase inhibitors focused
on musculoskeletal pain. [11,22,31] Zhou et al. described
aromatase inhibitors in combination with zoledronic acids and
pain. [11].
Synthesis per outcome measure is summarized and presented in
table 6, including levels of evidence.
Reduction in range of motion (ROM). Reduced ROM was
described in four systematic reviews [1,12,13,15] and six cohort
studies. [19,28,32–35] General reduction in ROM was described
[12,15,19,28,35] or specified for the shoulder in different
directions: abduction, or flexion/abduction and external rotation.
[32,33].
Regarding ALND as a medical intervention, one systematic
review reported a reduction in ROM in abduction and flexion
ranging from 132–175u, which was reported in 1–67% of the
patients. [15] Regarding SNB, a second systematic review
described a reduction in ROM. [12] Percentages of patients with
ROM reduction varied from 6%–31% after 12 months, and
reduced to 0%–9% after 24 months. Regarding ALND (directly or
after SNB) vs. SNB, change of ROM in the third systematic review
was reported in 9%–56% vs. 3%–24% of the patients, or in a
mean difference of 1u–20u within 12 months and 8%–20% vs.
0%–4% over 12 months. [13] Odds Ratios (ORs) in the included
studies of this systematic review ranged from 1.02–9.0 for
goniometric measurements. [13] One cohort study described a
reduced ROM of 21% vs. 56% at 6 months and 6% vs. 9% at
12 months, with an OR of 1.56 at 12 months. [32] Another
cohort study reported reduced ROM at six months and .
12 months in a study population in which 71% underwent ALND.
Reduction was present in 60% and 11% in flexion/abduction and
25% and 5% in external rotation [33]. ROM reduction was
related to ALND, a greater number of lymph nodes removed,
cording, seroma, mastectomy, stage II, hand dominance, BMI $
25 and older age (.65 years).
Regarding mastectomy vs. lumpectomy, one systematic review
presented an OR of 5.67 for mastectomy as a risk factor for
reduced ROM. [15] In one cohort study, ROM reduction was
present in 33% of the study population [34]. Mastectomy was
indicated as risk factor. Regarding ALND and mastectomy vs.
ALND, lumpectomy and radiotherapy reduced ROM was
described at one, 12 and 24 months in overall percentages and
percentages with severe reduction. Percentages reduced from 68%
vs. 73% to 23% vs. 30%. [28]
Regarding radiotherapy vs. no radiotherapy, one systematic
review presented ORs of 2.07–12.30, a relative risk (RR) of 4.6
and reduced ROM in 34%–52% vs. 4%–20% of the study
population in the included studies. [13] One large cohort study
presented an OR of 2.48 for radiotherapy as a risk factor for
ROM reduction. [32] Regarding axillary radiotherapy vs. no
axillary radiotherapy, the risk of decreased ROM was analyzed in
two systematic reviews (RR 2.6; OR 1.67). [1,15] A third
systematic review reported changes in joint mobility in 14% vs.
2% of the patients in one included study; ORs in other included
studies ranged from 1.70–6.83 for goniometric measurements.
Regarding radiotherapy to the axilla and chest vs. radiotherapy to
the chest, the same systematic review presented an RR of 1.7 in
one included study and reduced ROM in 20%–49% vs. 4%–14%
of the study population in other included studies. [13] Regarding
chemotherapy vs. no chemotherapy, one large cohort study
reported an OR of 0.73 of chemotherapy as a risk factor for ROM
reduction. [32].
In synthesizing the results from the included studies, we found
level 1 evidence for mastectomy and radiotherapy to the axilla as
risk factors for reduced ROM in abduction, flexion and external
rotation, and level 2 evidence for ALND and radiotherapy to the
chest wall.
Reduction in muscle strength. Reduced muscle strength
was reported in four systematic reviews [12,13,15,36] and five
cohort studies. [17,18,20,33,37].
Table 4. Quality test of methodology of the included systematic reviews based on the critical appraisal sheets of the Centre of
Evidence Based Medicine.
First author/year of
publication Search strategy
Inclusion criteria
selection
Quality of the
studies Results homogeneous Presentation of results Rating
Hickey et al. 201337 + + + + + 100%
Moja et al. 201214 + + + +/2 + 90%
Zhou et al. 201111 +/2 + +/2 + + 80%
Liu et al. 200912 +/2 + + +/2 2 60%
Tsai et al. 20091 +/2 + +/2 + + 80%
Lee et al. 200815 + + + +/2 + 90%
Levangie et al. 200813 +/2 + + + 2 70%
doi:10.1371/journal.pone.0096748.t004
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Regarding ALND, one systematic review described reduced
muscle strength (OR 3.03) [15]. One cohort study described
reduced muscle strength in 28% of the study population [20].
Regarding SNB, a second systematic review reported reduced
muscle strength in 17%–19% of the patients after sentinel node
biopsy and 11% in the long-term. [12] This systematic review
identified patients with young age (,50 years) as a risk factor for
muscle strength impairment based on results of one large study
comparing ALND vs. SNB. Regarding ALND (directly or after
SNB) vs. SNB, a third systematic review reported weakness in 48%
vs. 16% of the patients, with loss of abduction strength of 12–15
Nm, loss of grip strength of 12–41 Nm in the included studies and
ORs ranging from 5.14–8.82 reported in the included studies.
[13].
Regarding lumpectomy and ALND, one systematic review
reported reduced muscle strength in9%–28% of the study
population. [15] Regarding ALND and mastectomy vs. ALND,
lumpectomy and RT reduced muscle strength was described at
one, 12 and 24 months. [28] Percentages reduced from 67% vs.
72% to 39% vs. 56% reduced muscle strength. Reductions were
larger in the first 12 months compared to later measurements (see
table 6).
Regarding chest radiotherapy vs. no radiotherapy, the risk of
reduced muscle strength was analyzed in one systematic review.
[13] Extracted data from the included studies showed ORs from
1.70–6.83 for radiotherapy as a risk factor for reduced muscle
strength and one included study reported reduced muscle strength
in 14% vs. 2% of the patients. Regarding axillary radiotherapy vs.
radiotherapy to the chest wall, the risk of reduced muscle strength
was analyzed in the same systematic review. [13] One included
study reported an RR of 1.7; another study showed 59% vs. 40%
of the patients with reduced muscle strength. Regarding concur-
rent radiotherapy and chemotherapy vs. sequential radiotherapy
and chemotherapy, a fourth systematic review described the risk of
reduced muscle strength by concurrent treatment with an OR of
2.09. [36].
In synthesizing the results of the included studies, we found level
1 evidence for ALND, and concurrent radiotherapy and
chemotherapy as risk factors for reduced muscle strength. We
found level 2 evidence for SNB, radiotherapy to the chest wall and
radiotherapy to the axilla and chest as risk factors for reduced
muscle strength.
Pain. Pain was described in four systematic reviews
[11,12,15,36] and 10 cohort studies. [17,22,28,31,33,35,37–40].
Regarding ALND, one systematic review [15] and one cohort
study [38] described pain 12 months post-operative. This system-
atic review described an OR of 4.61 and percentages of shoulder
pain (9%–68%) and breast pain (15%–72%) in the individual
studies. [35] The cohort study described pain in 53% of the
population. [38] Regarding SNB, a second systematic review
reported pain in 8%–36% of the patients within 12 months and
8%–21% at 24 months, analyzing young age (,50 years) as a
predictive factor, described in one included study. [12] Regarding
ALND (directly or after SNB) vs. SNB, a third systematic review
reported pain during motion in one included study in 12% vs. 4%
at 12 months and 9% vs. 3% at 19 months and an OR of 3.54
mentioned in another study. [13].
Regarding ALND and mastectomy vs. ALND, lumpectomy and
radiotherapy pain was described at 1 month post-operatively, and
at 12 and at 24 months. [28] Pain reduced from 75% vs. 82% to
42% vs. 56%. Regarding chest radiotherapy vs. no radiotherapy,
one individual study in a systematic review reported at least weekly
pain in 26% vs. 4% of patients (OR = 7.10), 6 to 13 years post-
operatively. [13] Regarding concurrent radiotherapy and chemo-
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therapy vs. sequential radiotherapy and chemotherapy a fourth
systematic review reported the risk of brachial neuropathy (OR
3.14). [36] Regarding chemotherapy vs. no chemotherapy, two
cohort studies found chemotherapy to be a risk factor for pain,
[38] with a reported OR of 3.00. [40].
Regarding the administration of zoledronic acids vs. no
zoledronic acids, one systematic review reported the relative risk
(RR) of arthralgia (RR 1.16) and bone pain (RR 1.26). [11]
Regarding the upfront administration of zoledronic acids com-
pared to delayed administration, the same systematic review
described an increased risk of pain (RR 1.28). Regarding
exemestane vs. tamoxifen, one cohort study described an increased
risk of carpal tunnel syndrome (OR 9.90). [24] In this study, 43%
of the patients had a musculoskeletal disorder and 2% carpal
tunnel syndrome. Another cohort study described increased pain
incidence by using tamoxifen at baseline and at younger age (,
55 years). [22].
In general, pre-operative pain was a risk factor for post-
operative pain (OR 5.17) and prolonged pain. [24,40] Pain was
correlated with decreased muscle strength and range of motion,
decreased job participation, reduced use of the affected arm in
leisure activities and with lifting a gallon of milk or during heavy
household chores. [33] At 6 months, pain during daily activities
was less than at rest. [31,41] In contrast, one study reported an
exacerbation of pain by exercise. [40] Another study reported less
pain during activities compared to rest at six months post-
operative and more pain at 60 months. [39] Arm-shoulder pain
led to sleep disturbances (OR 3.17). [35].
In conclusion, we found level 1 evidence for ALND, radiother-
apy before chemotherapy, and the administration of zoledronic
acids (more in case of delayed administration) as risk factors for
pain. We found level 2 evidence for SNB and radiotherapy as risk
factors for pain.
Lymphedema. Lymphedema was described in three system-
atic reviews [1,12,15] and 20 cohort studies. [4,16–21,23,26–
30,32,34,39,42–45] Eight studies reported subjective data based
on a lymphedema questionnaire, [16,23,26,28] CTCAE, [21,27]
telephone interview, [23,26] or measured only 2 or 3 points of the
arm. [18,19].
Regarding ALND, two systematic reviews and five cohort
studies described an increased risk of lymphedema. One systematic
review described an RR of 3.47. [1] A second systematic review
described percentages of pain in the included studies ranging from
0%–34%. [15] Percentages in the cohort studies varied from
13%–30%. [20,29,39] BMI $30 as a risk factor for lymphedema
was described in one cohort study with an OR of 4.12 [44] and in
another cohort study as an increase of 4.1% or HR of 2.61 for
each lymph node removed. [26] Regarding SNB, a third
systematic review described percentages ranging from 3%–14%
in the first 12 months to 7% in the follow-up of 60 months. [12]
Figure 1. Flow diagram literature search adverse effects of breast cancer treatment.
doi:10.1371/journal.pone.0096748.g001
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Table 6. Adverse treatment effects in relation to impairments in upper extremities and thorax.
#12 months post-surgery .12 months post-surgery
Level of
evidence
Medical intervention %/p value/OR OR/RR/HR %/p-value
Reduction in ROM
ALND 1%–67%15 p = 0.000119 level 2
SNB At 12 months:
6%–31%%12
At 24 months:0%–9%12 level 3
SNB + ALND vs. SNB At 12 months:
24% vs. 24%/9%
vs. 3%13*; at 6
months: 56% vs.
21%; at 12 months:
9% vs. 6%. OR= 1.5632
OR= 1.02/2.65/9.013* At 18 months: 8% vs. 4%;
at .20 months: 20% vs. 0%;
at median 30 months 11%
vs. 4%13*
level 2
Mastectomy vs.
lumpectomy
OR= 5.67 (CI = 1.03–31.16)15 level 1
ALND level I–III +
mastectomy vs.
ALND level I–III +
lumpectomy + RT
At 1 month:68%
vs. 73%; at 12
months:32% vs.
40%28
At 24 months:23% vs. 30%28 level 3
RT chest wall vs. no
RT
OR= 2.07/6.60/12.3013*;
RR = 4.613; OR = 2.4832
34% vs. 20%/38% vs. 4%/52%
vs. 15%13*
level 2
RT axilla vs. no RT RR = 2.6 (CI = 1.42–4.03)1;
OR = 1.67 (CI = 0.98–2.86)15;
OR = 2.4835
level 1
RT axilla + chest wall
vs. RT chest wall
OR = 2.64/3.3713* 20% vs. 4%/Flexion 39%
vs. 4%; 24% vs. 5%/
Abduction 49% vs. 8%;
35% vs. 7%/External
rotation 45% vs. 14%;
41% vs. 13%13*
level 2
CT vs. no CT OR= 0.73, p = 0.00332 level 3
Reduction in muscle
strength
ALND OR= 3.03 (CI = 1.25–7.32)15 28%20 level 1
SNB 17–19%12 At 24 months: 11%12 level 2
SNB + ALND vs. SNB 36% vs. 8%13 OR= 8.8213 48% vs. 16% 13 level 2
ALND + Lumpectomy 9%–28%15 OR= 4.61 level 1
ALND level I–III +
mastectomy vs.
ALND
level I–III +
lumpectomy + RT
At 1 month:67%
vs. 72%; at 12
months:48%
vs. 51%28
At 24 months: 39% vs. 56%28 level 3
RT chest wall vs.
no RT
OR= 1.70/3.37/6.8313* 14% vs. 2%13 level 2
RT axilla + chest vs.
RT chest
RR = 1.713 59% vs. 40%13 level 2
Concurrent RT +
CT vs. sequential
OR = 2.09 (CI = 0.92–4.75)36 level 1
Pain
ALND OR= 4.61 (CI = 2.01–10.59)15 Shoulder pain 9%–68%15;
Breast pain 15%–72%14; 53%37
level 1
SNB 8–36%12 At 24 months:8–21%; at 60
months: SNB 9%12
level 2
SNB + ALND vs.
SNB
At 12 months:
12% vs. 4%13
OR= 3.54 (1.88–6.66)13 At 18 months: 9% vs. 3%13 level 2
ALND level I–III +
mastectomy vs.
ALND level I–III +
lumpectomy + RT
At 1 month: 75%
vs. 82%; at 12
months: 60%
vs. 63%28
At 24 months: 42% vs. 56%28 level 3
RT vs. no RT OR= 7.1013 At 6–13 years: weekly pain
26% vs. 4%13
level 2
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Table 6. Cont.
#12 months post-surgery .12 months post-surgery
Level of
evidence
Medical intervention %/p value/OR OR/RR/HR %/p-value
RT before CT vs.
RT after CT
Brachial neuropathy:
OR = 3.14 (CI = 0.12–79.39)36
level 1
CT vs. no CT OR= 3.00 (CI = 1.22–7.40)40 level 3
ZOL vs. no ZOL Arthralgia: RR = 1.16 (CI = 1.096–1.232);
Bone pain: RR = 1.26 (CI = 1.149–1.376)11
level 1
Delayed ZOL vs.
upfront ZOL
Bone pain: RR = 1.28 (CI = 1.135–1.453)11 level 1
Exemestane vs.
Tamoxifen
OR= 9.90 (CI = 3.52–27.82) for CTS24 level 3
Aromatase inhibitors; CT
(with/without taxanes)
Age ,55 vs. 55–65 vs.
.65 yrs: Arthralgia 46%
vs. 37% vs. 28%23;
CTS 2%, MSD 43%24
level 3
Lymphedema
ALND RR= 3.471; BMI .30: OR = 4.12
(CI = 1.58–10.72)43
0%–34%15/25%20/each
LN removed 4.1% q26/
HR = 2.61(CI = 1.77–3.84)26.
At 60 months: 30%33/13%39
level 1
SNB At 6 month: 3–10%; at
12 months: 6–14%12
7%12 level 2
SNB + ALND vs. SNB 13% vs. 9%35/3%
vs. 0%44
RR = 3.07 (no ALND 3.47)1/OR = 11.67
(CI = 1.45–93.65)15/OR = 6.61
(CI = 1.64–26.57)18
35% vs. 5%19/14% vs. 8%32 level 1
Mastectomy Radical mastectomy vs. other mastectomy
RR= 3.281; Modified radical mastectomy
OR= 7.48 (CI = 2.38–23.85)20
level 1; level 3
ALND level I–III +
mastectomy vs.
ALND level I–III +
lumpectomy + RT
At 1 month:27% vs. 41%;
at 12 months:26% vs. 48%28
At 24 months: 33% vs. 52%28 level 3
Reconstruction vs.
no reconstruction
5% vs. 18%42 level 4
RT axilla vs. RT not
axilla
RR = 2.971/OR = 2.412/OR= 3.5717 level 1
Concurrent vs.
sequential RT after CT
OR= 2.02 (CI = 0.18– 22.61)36 level 1
RT before CT vs. RT
after CT
OR= 2.11 (CI = 0.67–7.21)35 level 1
CT vs. no CT HR= 1.46 (CI = 1.04–2.04)26 level 3
Reduction in level of
activities in daily living
ALND vs. SNB Qarm use: p,0.0013 OR= 3.18/9.2313* level 2
ALND + mastectomy vs.
ALND + lumpectomy
shoulder/arm function,
social and work activities:
p = 0.0013
level 3
SNB + ALND vs. SNB vs.
lumpectomy
At 3 months:39% vs. 18%
vs. 12%; at 6 months:40%
vs. 12% vs. not described;
at 12 months: 44% vs.
19% vs. 18%46
Pain during activities vs.
at rest 36% vs. 30%40/Daily
activitiesQ, lifting objectsQ
25–35%; problems with
transportation 14%; gave up
hobbies or sports 37%17
level 2
Impairments in Arm and Shoulder in Breast Cancer
PLOS ONE | www.plosone.org 13 May 2014 | Volume 9 | Issue 5 | e96748
Regarding ALND (directly or after SNB) vs. SNB, two systematic
reviews and three cohort studies described lymphedema. One
systematic review reported an RR of 3.07 (when compared to no
axillary dissection 3.47), [1] while another systematic review
reported an OR of 11.67. [15] In the cohort studies, percentages
of patients with lymphedema varied from 3%–13% vs. 0%–9% in
the first 12 months to 14%–35% vs. 5%–8% in longer follow up.
[19,32,43].
Regarding mastectomy, lymphedema was described in one
systematic review and one cohort study. The systematic review
reported an RR of 3.28, [1] while the cohort study reported an
OR of 7.48. [20] Regarding ALND and mastectomy vs. ALND,
lumpectomy and radiotherapy lymphedema was described at one
month post-operatively, and at 12 and at 24 months. [28]
Percentages of patients with lymphedema increased from 27%–
41% at one month to 33%–52% at 24 months post-operatively.
Regarding breast reconstruction vs. no reconstruction, one
cohort study described lymphedema in 5% vs. 18% of the study
population. [42].
Regarding radiotherapy to the chest and axilla vs. radiotherapy
to the chest, two systematic reviews and one cohort study
described lymphedema. One systematic review described an RR
of 2.97, [1] the second an OR of 2.4. [12] The cohort study
reported an OR of 3.57. [17] Regarding concurrent radiotherapy
and chemotherapy vs. sequential radiotherapy and chemotherapy,
one systematic review reported an OR of 2.02. [36] Regarding
radiotherapy before chemotherapy vs. radiotherapy after chemo-
therapy, the same systematic review reported an OR of 2.11.
Regarding chemotherapy vs. no chemotherapy, one cohort
study reported a Hazard Ratio (HR) of 1.46. [26] The risk of
lymphedema in relation to chemotherapy was investigated in this
cohort study in patients with ALND, comparing multi-agent
chemotherapy with chemotherapy with anthracyclines. Regarding
chemotherapy with radiotherapy vs. chemotherapy without
radiotherapy, HRs in this study varied from 0.30–4.09 vs. 3.78–
5.46.
The overall incidence of lymphedema increased over time,
except in one study where lymphedema decreased because of
decongestive lymphatic therapy. [18] One case control study
described the risk of lymphedema due to infection in patients with
ALND (OR 3.80). [30] BMI $30 as risk factor for lymphedema
was described in one systematic review in patients with SNB as
weak evidence, not providing data [12] and in two cohort studies
(OR 3.59; adjusted for ALND OR = 4.1), [44] while an OR of
2.01 was found for BMI .25. [20] One study followed patients
five years after ALND and provided nomograms that indicated a
BMI .30 as a risk factor as well. [29] The influence of age on the
development of lymphedema was described in one systematic
review and four cohort studies, indicating young age (,50 years)
[12,16,32] and age .65 years [30] as risk factors and increasing
by age in another cohort study. [29].
One study reported that comorbidity led to a higher incidence
of lymphedema. [17]
We found level 1 evidence for ALND, radical mastectomy,
radiotherapy to the axilla, concurrent radiotherapy and chemo-
therapy, and radiotherapy before chemotherapy as risk factors for
lymphedema.
Reduction in activities in daily living. Limitations in
activities in daily living were described in two SRs [12,13] and
eight cohort studies. [3,17,28,33,38,41,45,46].
Regarding ALND, one cohort study reported decreased degree
of daily activities. [17] Regarding ALND vs. SNB one systematic
review and one cohort study described an increased risk of
problems in performing daily activities. [3,13] ORs were
calculated in two included studies in the systematic review (resp.
3.18 and 9.23). [13] Reported ORs for performing different tasks
in one of the included studies in the systematic review varied from
2.13–2.34 when stratified by age, with age between 65 and
74 years at most risk and between 40 and 54 years at least risk
Table 6. Cont.
#12 months post-surgery .12 months post-surgery
Level of
evidence
Medical intervention %/p value/OR OR/RR/HR %/p-value
ALND level I–III +
mastectomy vs. ALND
level I–III +
lumpectomy + RT
At 1 month:LiftingQ 83%
vs. 88%; household chores
61% vs. 64%; self-careQ
56% vs. 63%; physical
activitiesQ 73% vs. 76%.
At 12 months:LiftingQ
34% vs. 39%; household
choresQ 28 vs. 33%;
self-careQ 16% vs. 12%;
physical activitiesQ 41%
vs. 39%28
At 24 month: LiftingQ 20% vs. 39%;
household choresQ 18% vs. 21%;
self-careQ 10% vs. 14%; physical
activities: 34% vs. 31%28
level 3
RT chest wall vs.
no RT
OR= 1.3213 29 vs. 4%13 level 2
RT axilla + chest
wall vs. RT chest
wall
OR = 2.64/4.6713* level 2
CE+T or CEF 34%39 level 3
Intervention: ALND, axillary lymph node dissection; CEF, cyclophosphamide, epirubicin and fluorouracil; CE+T, cyclophosphamide, epirubicin + docetaxel; CT,
chemotherapy; HT, hormonal therapy; LN, lymph node; MRM, modified radical mastectomy; RM, radical mastectomy; RT, radiotherapy; SC, supraclavicular; SNB, sentinel
node biopsy; vs., versus.
Outcomes: CTS, carpal tunnel syndrome; HR, hazard ratio; MSD, musculoskeletal disorder OR, odds ratio; RR, relative risk; ZOL, zoledronic acids; *, data extracted from
included studies.
doi:10.1371/journal.pone.0096748.t006
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compared to a non-breast cancer population. Decline in one or
more tasks was described in another included study (34% vs. 50%,
OR 0.8). One cohort study described the avoidance of normal arm
use in cases of ALND compared to SNB (p ,0.001). [3]
Regarding ALND (directly or after SNB) vs. SNB vs. lumpectomy,
one cohort study described a decline of activities in the first year
post-operatively in 39%–44% of the patients after ALND, 18%–
19% in case of SNB and 12%–19% in case of lumpectomy. [45]
Regarding ALND and mastectomy vs. ALND and lumpectomy,
one cohort study reported more problems in arm and shoulder
function, conducting social activities and work in the lumpectomy
group (p,0.001). [3] Regarding ALND and mastectomy vs.
ALND, lumpectomy and radiotherapy, daily activities were
described at 1 month post-operatively, at 12 and at 24 months
in overall percentages and percentages with severe decline in daily
activities. [28] Percentages reduced over time, with more problems
in the lumpectomy group. Regarding chest wall radiotherapy vs.
no radiotherapy, one systematic review reported a decline in daily
activities with ORs in three individual studies (resp. 1.32, 8.0 and
10.67) and percentages of 29% vs. 4% in another included study.
[13] Regarding radiotherapy to the axilla and chest wall vs.
radiotherapy to the chest alone, the same systematic review
reported an OR of 2.64 in one included study. Regarding
chemotherapy with cyclophosphamide, epirubicin and docetaxel
vs. chemotherapy with cyclophosphamide, epirubicin and fluor-
acil, one cohort study described a higher risk in giving up daily
activities (OR 1.59). [38] Overall, 34% of the population in this
study showed a decline in the level of daily activities.
Overall, one cross-sectional study described a decline in
activities in 31% of the population. [34] One cohort study related
radiotherapy to later starting remunerable work. [41] Activity level
did not return to the pre-operative level within one year, [46] and
at 10 months, 83% of the patients returned to work. [41] Young
age as a predictive factor for a reduced number of metabolic
equivalents was described in one cohort study. [46] Another
cohort study described reduced use of the affected arm in leisure
activities and with lifting a gallon of milk or during heavy
household chores in relation to pain and feeling weak. [33].
Comorbidity was related to a decreased level of activities in
daily living. [17].
We found level 2 evidence for ALND and radiotherapy,
especially when the axilla was involved, as risk factors for
decreasing the degree of daily activities.
Discussion
In this systematic review, we showed that breast cancer
treatment results in multiple impairments in the arm and shoulder.
We analyzed adverse effects for different components of breast
cancer treatment and related these to the integrated treatment of
breast cancer. Previous systematic reviews, as well as a part of the
cohort studies included in this study, merely focused on only a part
of the medical treatment and/or outcome measurements, while
others only looked at a general level, without distinction between
components. By distinguishing between each treatment modality
and outcome measurement, we are the first to analyze the risk of
each component of breast cancer treatment. We showed that
patients treated with ALND are at the highest risk of developing
impairments of the arm and shoulder. Reduced ROM and muscle
strength, pain, lymphedema and decreased degree of activities in
daily living were reported most frequently in relation to ALND.
Lumpectomy was related to a decline in the level of activities of
daily living. Radiotherapy and hormonal therapy were the main
risk factors for pain.
An integrated approach in assessing the adverse effects of
distinct breast cancer treatment modalities on impairments in arm
and shoulder function is of clinical importance. Recovery from
adverse effects can be addressed in multidisciplinary treatment of
patients; for example, physical therapy may be suitable for the
recovery of ROM, muscle strength, lymphedema and daily
activities. In general, we expect that awareness and timely referral
are very relevant for patients with impairments interfering with
daily activities in early recovery [47]. More attention should be
paid to scapular coordination and muscle strength in the early
post-operative phase, as these impairments were reported even up
to six years post-operatively. [12,13,15,37] We noticed that the
included studies focused more on impairments in function than on
activities of daily living or participation in remunerable work,
hobbies and social activities. In future research, more awareness of
these issues is warranted, as performing activities is an important
outcome for quality of life. This will further build the body of
knowledge for regaining full recovery of activities of patients with
breast cancer in a multidisciplinary approach.
Unfortunately, due to the large variety in medical treatments
and outcome measures, we could not perform a meta-analysis of
our data. This emphasizes the importance of uniform description
of treatment, analysis of outcomes, and use of uniform measure-
ment instruments. Validated measurement instruments are
important in assessing outcomes of treatments. We found a large
variability of instruments, which made it difficult to compare
studies and conduct a meta-analysis. This conclusion was also
stated by authors of several included systematic reviews in our
study [12,13,15]. International consensus regarding measurement
instruments and the way of using them should be encouraged.
From our review it became clear that reduced ROM, pain and
lymphedema are the most commonly described impairments.
ROM decreased, especially in the first month post-operatively. As
most systematic reviews presented data only for long-term follow-
up after treatment, reductions in the first month were less noticed,
but when described in cohort studies significance existed. After
12 months, percentages of patients with reduction in ROM and
differences in ROM between the affected and unaffected shoulder
were reduced but still existed. Wide variation of percentages shows
the variability in defining ROM impairment and the way of
measurement.
The incidence of lymphedema increased over time. One study
reported a very high incidence of lymphedema after one month.
[28] This may be due to real lymphedema or rather seroma or
radiotherapy-induced breast infection. [48].
The study of Ozcinar et al. [18] showed that treatment of
lymphedema decreased its severity. In general, the reported
percentages of patients with lymphedema were higher when
lymphedema was measured by a questionnaire. The Norman
questionnaire appeared to be sensitive for detection, but not
specific, [10] and may be used as an initial tool in detecting
lymphedema. Volume is the most important outcome for
lymphedema diagnosis and treatment evaluation; therefore, the
questionnaire should be followed by tape measurement (calculated
to volume) or water volumetry or perometry. Arm volume is also
associated with Body Mass Index and body composition.
Therefore we advocate to use percentage difference between arms
(where A is the affected arm and U is the unaffected arm)
A{U
U
 
|100
or to use the formula for relative volume change (RVC) to
determine outcome over time.
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A2=U2
A1=U1
{1
Activities in daily living and participation are important
parameters for quality of life. Limitation in body functions and
structures may be restrictive in performing activities and
participating in social events. Only one systematic review [13]
and six cohort studies [3,17,28,38,41,46] described limitations in
activities and only three cohort studies described problems in
participation. As half of the patients with breast cancer were of
working age, more attention should be paid to daily activities,
work capacity, hobbies and sports.
Several limitations to our study should be noted. Our cut-off
point with a quality score .50% is to some extent arbitrary and
may have resulted in the exclusion of valuable data in our analysis.
Main reasons for the low quality scores of excluded studies were
issues with subgroup analysis, lack of outcome measures, poor
presentation of results and lack of sufficient follow-up. Firstly, we
analyzed which articles in our search were included in the
systematic reviews. Four systematic reviews were excluded: based
on treatment before 2000 or with low quality score. The review
with low quality score was narrative and based on retrospective
data. We therefore think the exclusion of these studies has avoided
bias and contribute to the robustness of our conclusions. Based on
the homogeneity of the results our choice seems to be justified.
Another point is that, instead of relying on the review synthesis, it
would have been a possibility to use existing reviews as sources to
identify primary data, which would increase the value of the
paper. We choose to follow the recommendations according the
Oxford Centre of Evidence-Based Medicine. In this system
systematic reviews are one of the factors in evidence classification.
If it would have been possible to perform a meta-analysis the
original data would have been extracted from the reviews.
However, as described, this was not possible. We deemed
additional analysis not to be of added value for the purpose of
our paper. Therefore we used quality scores to test the credibility
of the conclusions of the original authors and used these in the
synthesis. Adverse effects of radiotherapy that may influence
limitations in arm and shoulder function, such as fibrosis of the
skin and sub cutis, were not included in our study. In addition,
adverse effects of chemotherapy and target therapy on general
cardiopulmonary capacity were not included. Other reported
symptoms such as sleep disturbances, weight gain, cardiac function
and sensory disturbances have not been reported, as have anxiety
and depression, while these problems may influence the capacity
of performing daily activities.
Conclusions
Patients with breast cancer suffer from constraints in arm and
shoulder in the first year post-operative and at long-term follow-
up. Patients treated with ALND are most at risk for developing
impairments of the arm and shoulder. Reduced ROM and muscle
strength, pain, lymphedema and decreased degree of activities in
daily living were reported most frequently in relation to ALND.
Lumpectomy was related to a decline in the level of activities of
daily living. Radiotherapy and hormonal therapy were the main
risk factors for pain.
An integrated approach in addressing the adverse effects of
distinct breast cancer treatment modalities on impairments in arm
and shoulder function is of clinical relevance. Patients treated with
ALND require special attention to detect and consequently
address impairments in the arm and shoulder. Patients with pain
should be monitored carefully, because pain limits the degree of
daily activities.
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